• Publications
  • Influence
Use of L-asparaginase in childhood ALL.
  • H. Müller, J. Boos
  • Biology, Medicine
    Critical reviews in oncology/hematology
  • 1 August 1998
L‐asparaginase treatment in acute lymphoblastic leukemia
There is an overview of available evidence for optimal use of Erwinia asparaginase in the treatment of ALL and debate on the optimal formulation and dosage of these agents continues.
High Frequency of p53/MDM2/p14ARF Pathway Abnormalities in Relapsed Neuroblastoma
The results show that a high proportion of neuroblastomas which relapse have an abnormality in the p53 pathway, suggesting that agents which reactivate wild-type p53 would be beneficial, in contrast to those with downstream defects in which p53-independent therapies are indicated.
Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial
Consistently favorable results in non-HR patients were achieved with significant treatment reduction in the majority of these patients, and compared without previous trial ALL-BFM 90, consistently favorable results were achieved.
Level of activity in children undergoing cancer treatment
In the present study physical activity in patients undergoing cancer therapy was quantified in order to determine the extent of the restriction and to provide baseline information for the assessment of possible interventions.
Idarubicin improves blast cell clearance during induction therapy in children with AML: results of study AML-BFM 93
A significant better blast cell reduction in the bone marrow on day 15 in patients of the idarubicin arm showed a better efficacy than of daunorubsicin during induction with a similar rate of toxicity.
Pegylated asparaginase (OncasparTM) in children with ALL: drug monitoring in reinduction according to the ALL/NHL‐BFM 95 protocols
Children treated with native Escherichia coli asparaginase in induction therapy of acute lymphoblastic leukaemia or non‐Hodgkin's lymphoma were switched to the pegylated enzyme for reinduction under drug monitoring, with good results.
Treatment of children with metastatic soft tissue sarcoma with oral maintenance compared to high dose chemotherapy: Report of the HD CWS‐96 trial
This work prospectively studied the efficacy of high dose therapy (HDT) versus an oral maintenance treatment (OMT) in patients with stage IV soft tissue sarcoma (STS) and found no significant difference between the two treatments.